170.13
前日終値:
$170.64
開ける:
$168.43
24時間の取引高:
580.65K
Relative Volume:
0.64
時価総額:
$8.37B
収益:
$4.06B
当期純損益:
$413.08M
株価収益率:
21.24
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
+0.02%
1か月 パフォーマンス:
+11.28%
6か月 パフォーマンス:
+59.60%
1年 パフォーマンス:
-11.91%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
CRL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRL
Charles River Laboratories International Inc
|
170.13 | 8.40B | 4.06B | 413.08M | 560.48M | 8.01 |
![]()
TMO
Thermo Fisher Scientific Inc
|
525.83 | 198.09B | 43.21B | 6.58B | 6.17B | 17.28 |
![]()
DHR
Danaher Corp
|
206.15 | 146.89B | 24.01B | 3.41B | 4.86B | 4.7082 |
![]()
IDXX
Idexx Laboratories Inc
|
636.91 | 50.67B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
138.04 | 39.19B | 6.79B | 1.22B | 1.09B | 4.2644 |
![]()
IQV
Iqvia Holdings Inc
|
204.76 | 34.64B | 15.70B | 1.24B | 2.01B | 6.9036 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-10-06 | アップグレード | William Blair | Mkt Perform → Outperform |
2025-10-02 | アップグレード | Barclays | Equal Weight → Overweight |
2025-09-09 | アップグレード | Jefferies | Hold → Buy |
2025-07-09 | アップグレード | Citigroup | Neutral → Buy |
2025-05-23 | アップグレード | Redburn Atlantic | Neutral → Buy |
2025-05-14 | アップグレード | TD Cowen | Hold → Buy |
2025-05-08 | アップグレード | Evercore ISI | In-line → Outperform |
2025-03-21 | ダウングレード | Goldman | Buy → Neutral |
2025-03-04 | アップグレード | Citigroup | Sell → Neutral |
2025-03-03 | アップグレード | Redburn Atlantic | Sell → Neutral |
2025-01-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
2025-01-17 | ダウングレード | UBS | Buy → Neutral |
2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
2024-11-07 | アップグレード | CLSA | Underperform → Hold |
2024-10-23 | 開始されました | CLSA | Underperform |
2024-10-14 | 開始されました | Redburn Atlantic | Sell |
2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-06-28 | ダウングレード | Argus | Buy → Hold |
2024-06-07 | 開始されました | Mizuho | Neutral |
2024-06-06 | 開始されました | Goldman | Buy |
2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
2023-09-13 | 開始されました | TD Cowen | Market Perform |
2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
2022-09-30 | アップグレード | Jefferies | Hold → Buy |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 開始されました | Guggenheim | Neutral |
2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
2022-04-07 | 開始されました | Stephens | Overweight |
2022-02-17 | 繰り返されました | BofA Securities | Buy |
2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
2022-02-17 | 繰り返されました | UBS | Buy |
2021-08-05 | 再開されました | Credit Suisse | Neutral |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-09-10 | アップグレード | Jefferies | Hold → Buy |
2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
2020-05-13 | アップグレード | UBS | Neutral → Buy |
2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 開始されました | Deutsche Bank | Buy |
2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | アップグレード | Goldman | Neutral → Buy |
2020-01-08 | 開始されました | Wells Fargo | Overweight |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-06-10 | 開始されました | SVB Leerink | Outperform |
2019-04-30 | 再開されました | Evercore ISI | Outperform |
2018-12-14 | 開始されました | Deutsche Bank | Buy |
2018-10-09 | 開始されました | UBS | Neutral |
2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Can you recover from losses in Charles River Laboratories International Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Market Trend Review & Step-by-Step Trade Execution Guides - newser.com
Key resistance and support levels for Charles River Laboratories International Inc.Quarterly Investment Review & Weekly Hot Stock Watchlists - newser.com
A Look at Charles River Laboratories' Valuation Following Strategic ReproTracker Partnership with Toxys - simplywall.st
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call - Business Wire
How to integrate Charles River Laboratories International Inc. into portfolio analysis toolsJuly 2025 Final Week & Growth-Oriented Investment Plans - newser.com
Why hedge funds are buying Charles River Laboratories International Inc. stockJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Will Charles River Laboratories International Inc. (RV6) stock sustain uptrend momentumJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Will Charles River Laboratories International Inc. bounce back from current supportQuarterly Profit Review & Target Return Focused Stock Picks - newser.com
Tick level data insight on Charles River Laboratories International Inc. volatilityEntry Point & Real-Time Buy Signal Alerts - newser.com
Understanding Charles River Laboratories International Inc.’s price movement2025 Technical Patterns & Risk Managed Investment Signals - newser.com
TD Cowen Adjusts Price Target on Charles River Laboratories International to $205 From $179, Maintains Buy Rating - MarketScreener
Charles River Laboratories (CRL): Investor Outlook Reveals Potential 8.68% Upside - DirectorsTalk Interviews
Allspring Global Investments Holdings LLC Acquires 516,521 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Sold by Truist Financial Corp - MarketBeat
Could Charles River (CRL) Redefine Its Competitive Edge with New Non-Animal Toxicology Platform? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Lawson Kroeker Investment Management Inc. NE - MarketBeat
Janney Montgomery Scott LLC Has $1.58 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs (CRL): Examining Valuation Following Recent Share Price Rebound - Yahoo Finance
Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Why Charles River Laboratories International Inc. (RV6) stock is trending on social mediaGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Published on: 2025-10-10 13:12:55 - newser.com
Why Charles River Laboratories International Inc. stock is seen as undervaluedExit Point & Expert Approved Momentum Ideas - newser.com
Can Charles River Laboratories International Inc. stock deliver strong Q4 earningsWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Weiss Ratings Reiterates "Sell (D)" Rating for Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock prediction for this weekCPI Data & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 06:30:08 - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is Charles River Laboratories International Inc. (RV6) stock positioned for digital growth eraInsider Buying & Stock Portfolio Risk Control - newser.com
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - BioSpace
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks - FinancialContent
What drives Charles River Laboratories International Inc stock priceMorning Star Patterns & High Yield Portfolio Picks - earlytimes.in
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicit - PharmiWeb.com
Charles River, Toxys Form Partnership on Use of Drug Toxicity Detection Tool - MarketScreener
Charles River (CRL) Partners with Toxys to Enhance Toxicity Testing - GuruFocus
Charles River Laboratories Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
HB Wealth Management LLC Invests $306,000 in Charles River Laboratories International, Inc. $CRL - MarketBeat
State of Alaska Department of Revenue Sells 10,403 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (NYSE:CRL) Downgraded by Wall Street Zen to Buy - MarketBeat
William Blair Upgrades Charles River Laboratories International (CRL) - Nasdaq
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
William Blair Upgrades Charles River (CRL) to Outperform | CRL S - GuruFocus
Is now a turning point for Charles River Laboratories International Inc.Quarterly Earnings Summary & Real-Time Volume Surge Alerts - newser.com
Will Charles River Laboratories International Inc. (RV6) stock outperform benchmarks2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Charles River Laboratories International, Inc. $CRL is Laurus Global Equity Management Inc.'s 4th Largest Position - MarketBeat
Sendero Wealth Management LLC Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):